glp 1 and lupus The anti-inflammatory immunological properties of GLP-1 Receptor Agonists Association between autoimmune diseases and
Description
These methodological limitations temper the strength of the conclusions and preclude a quantitative synthesis, highlighting the urgent need for prospective, dedicated ophthalmic RCTs

These numbers come from separate clinical trial programs and should not be used as a direct head-to-head comparison

Phytochemicals for the treatment of metabolic diseases: Evidence from clinical studies

Jardine, R

A full-dose, clinician-guided option with titration tailored to your body

Obesity is now very common among patients with Crohns disease, yet there is limited guidance on how newer metabolic medications, particularly GLP-1 receptor agonists affect Crohns-related outcomes, presenting author Nakul Ganju, MD, an internal medicine resident at Howard University Hospital in Washington, DC, told GI & Hepatology News